5912-35-6

Usage

Uses

Used in Pharmaceutical Research and Development:
8-Bromo-1,7-naphthyridin-6-amine is utilized as a key intermediate in the synthesis of pharmaceutical compounds. Its presence of a bromine atom and amine group allows for further chemical modifications, making it a versatile building block for the development of new drugs with potential therapeutic applications.
Used in Organic Synthesis:
In the field of organic synthesis, 8-Bromo-1,7-naphthyridin-6-amine serves as a valuable precursor for the production of other organic compounds. Its reactivity and structural features facilitate its use in a range of chemical reactions, contributing to the creation of novel organic molecules with diverse properties and potential applications.
Used in Heterocyclic Chemistry Research:
8-Bromo-1,7-naphthyridin-6-amine is employed as a model compound in the study of heterocyclic chemistry. Its unique structure provides insights into the properties and reactivity of fused heterocyclic systems, aiding researchers in understanding the fundamental principles of heterocyclic chemistry and guiding the design of new heterocyclic compounds with specific functionalities.
Used in Chemical Reactions and Synthesis Processes:
8-Bromo-1,7-naphthyridin-6-amine is used as a reactant in various chemical reactions and synthesis processes. Its bromine atom and amine group enable it to participate in a wide array of reactions, such as nucleophilic substitutions, electrophilic aromatic substitutions, and cross-coupling reactions, leading to the formation of new compounds with potential applications in various industries.

InChI:InChI=1/C8H6BrN3/c9-8-7-5(2-1-3-11-7)4-6(10)12-8/h1-4H,(H2,10,12)

Upstream product

• 20970-75-6 2-cyano-3-methylpyridine 
• 116986-13-1 2-cyano-3-(bromomethyl)pyridine 
• 6443-85-2 3-pyridinylacetonitrile 
• 6635-88-7 3-(cyanomethyl)pyridine 1-oxide 
• 5912-34-5 2-cyano-pyridin-3-yl-acetonitrile 

Downstream Products

• 106309-54-0 6-amino-8-morpholino-1,7-naphthyridine 
• 1201843-32-4 N-(2-chloro-5-(1,7-naphthyridin-6-yl)pyridin-3-yl)-4-fluorobenzenesulfonamide 
• 524734-44-9 8-(3-methoxyphenyl)-1,7-naphthyridin-6-yl trifluoromethanesulfonate 
• 1295626-56-0 4-(8-ethyl-1,7-naphthyridin-6-yl)benzoic acid 
• 1295626-55-9 methyl 4-(8-ethyl-1,7-naphthyridin-6-yl)benzoate 
• 5912-36-7 1,7-naphthyridin-6-amine 
• 207278-99-7 6-amino-8-(3-nitrophenyl)-1,7-naphthyridine 
• 713145-54-1 8-(5-fluoro-2-methoxy-phenyl)-[1,7]naphthyridin-6-ylamine 
• 713145-53-0 8-(3-fluoro-phenyl)-[1,7]naphthyridin-6-ylamine 
• 207279-23-0 NVP 
• 261960-44-5 6-trifluoromethylsulfonyloxy-8-(3-nitrophenyl)-1,7-naphthyridine 
• 207279-10-5 6-(4-carboxyphenyl)-8-(3-cyanophenyl)-1,7-naphthyridine 

Relevant academic research and scientific papers

METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS

The subject matter described herein is directed to ferroportin inhibitor compounds of Formula (I) and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and methods of administering the compounds for prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, particularly iron overload states, such as thalassemia, sickle cell disease and hemochromatosis, and also kidney injuries.

SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER

Disclosed are compounds of Formula (I) or a salt thereof, wherein Ring A is a carbon-linked ring; and Ring A, R1, and n are defined herein. Also disclosed are methods of using such compounds to inhibit Helios protein, and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.

Compound used as EGFR kinase inhibitor and application thereof

The invention relates to a compound used as an EGFR kinase inhibitor and application thereof, the compound has a structure as shown in a formula I, and the compound can be used for adjusting EGFR kinase activity or treating related diseases, especially non-small cell lung cancer.

Compound useful as RET kinase inhibitors, and uses thereof

The invention belongs to the technical field of medicine, and particularly discloses a compound represented by a formula (I), a formula (II), a formula (III) or a formula (IV), or a pharmaceutically acceptable salt, a stereoisomer, a solvate or a prodrug thereof, wherein each symbol is defined in the claims. The compound provided by the invention can be used as a medicine for regulating RET kinaseactivity or treating RET related diseases.

Solubility-driven optimization of phosphodiesterase-4 inhibitors leading to a clinical candidate

The solubility-driven optimization of a series of 1,7-napthyridine phosphodiesterase-4 inhibitors is described. Directed structural changes resulted in increased aqueous solubility, enabling superior pharmacokinetic properties with retention of PDE4 inhib

Phospshoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) dual inhibitors: Discovery and structure-activity relationships of a series of quinoline and quinoxaline derivatives

The phosphoinositide 3-kinase (PI3K) family catalyzes the ATP-dependent phosphorylation of the 3′-hydroxyl group of phosphatidylinositols and plays an important role in cell growth and survival. There is abundant evidence demonstrating that PI3K signaling is dysregulated in many human cancers, suggesting that therapeutics targeting the PI3K pathway may have utility for the treatment of cancer. Our efforts to identify potent, efficacious, and orally available PI3K/mammalian target of rapamycin (mTOR) dual inhibitors resulted in the discovery of a series of substituted quinolines and quinoxalines derivatives. In this report, we describe the structure-activity relationships, selectivity, and pharmacokinetic data of this series and illustrate the in vivo pharmacodynamic and efficacy data for a representative compound.

Elucidation of a structural basis for the inhibitor-driven, p62 (SQSTM1)-dependent intracellular redistribution of cAMP phosphodiesterase-4A4 (PDE4A4)

Figure Presented. A survey of PDE4 inhibitors reveals that some compounds trigger intracellular aggregation of PDE4A4 into accretion foci through association with the ubiquitin-binding scaffold protein p62 (SQSTM1). We show that this effect is driven by i

A scalable synthesis of a 1,7-naphthyridine derivative, a PDE-4 inhibitor

A six-step synthesis of a 4-[8-(3-fluorophenyl)[1,7]naphthyridin-6-yl]- trans-cyclohexanecarboxylic acid with an overall yield of 27% starting from 2-cyano-3-methylpyridine, cyclohexane-1,4-dicarboxylic acid dimethyl ester, and 3-fluorophenylboronic acid is described. The trans stereochemistry in the cyclohexane moiety was achieved through a series of equilibration steps at different stages of the synthesis.

INHIBITORS OF PI3 KINASE

The present invention relates to compounds of Formula (I), or a pharmaceutically acceptable salt thereof; methods of treating diseases or conditions, such as cancer, using the compounds; and pharmaceutical compositions containing the compounds, wherein Q, X1, X2, R1 and Z are as defined herein.

Palladium-catalyzed cross-coupling reactions for the synthesis of 6,8- disubstituted 1,7-naphthyridines: A novel class of potent and selective phosphodiesterase type 4D inhibitors

Recently, four subtypes of the human phosphodiesterase type 4 (PDE4A-D) enzyme have been described. So far, only very few PDE4 subtype-selective inhibitors are known. Herein, we describe the synthesis of 6,8-disubstituted 1,7-naphthyridines and their characterization as potent and selective inhibitors of PDE4D which suppress the oxidative burst in human eosinophils with IC50 values as low as 0.7 nM. SAR development and the extended use of palladium-catalyzed cross-coupling reactions led to compound 11 which inhibited human PDE4D with an IC50 value of 1 nM. Thus, compound 11 was 55, 175, and 1000 times more potent in inhibiting PDE4D over PDE4B, PDE4A, and PDE4C. In a Brown Norway rat model of allergic asthma, compound 11 when given by the oral route (1 mg/kg) reduced by more than 50% the influx of eosinophils, T-cells, and neutrophils into bronchoalveolar lavage fluid (BALF) samples obtained from antigen-challenged animals. Thus, PDE4D- selective inhibitors of the 1,7-naphthyridine class have the potential as an oral therapy for treating asthma.